Chronic Graft Versus Host Disease - 29 Studies Found
| Completed |
: Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease : Oral Chronic Graft-versus-host Disease : 2008-05-27 :
|
| Withdrawn |
: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease : Active Chronic Graft Versus Host Disease : 2009-10-26 : Drug: Pentostatin; Cyclophosphamide; Rituximab Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophospha |
| Active, not recruiting |
: Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) : Chronic GVHD : 2010-04-16 :
|
| Recruiting |
: Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) : Refractory Chronic Graft Versus Host Disease (cGVHD) : 2015-01-14 : Device: Photopheresis Theraflex ECP™ The Macopharma (Theraflex ECP™) approach is based on a |
| Recruiting |
: Treatment of Chronic GVHD of Liver or Lungs by ECP : Chronic Graft-Versus Host Disease : 2006-01-03 : Procedure: Extracorporeal photoimmunotherapy |
| RECRUITING |
: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. : Chronic Graft Versus Host Disease : 2024-11-21 : Pharmaceutical form:Tablet-Route of administration:oral |
| RECRUITING |
: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease : Chronic Graft Versus Host Disease : 2024-11-21 : Given PO |
| NOT_YET_RECRUITING |
: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease : Chronic Graft Versus Host Disease : 2024-11-21 : 200mg PO QD x 24 cycles (28-day cycle) |
| COMPLETED |
: Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) : Chronic Graft Versus Host Disease : 2024-11-21 : The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose l |